NCT06683612

PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF

A Phase 1b, Open-label Study of PIPE-791 to Determine Brain and Lung Lysophosphatidic Acid Receptor 1 (LPA1) Occupancy, by [18F] PIPE-497 PET Imaging in Healthy Volunteers, Volunteers With Progressive Multiple Sclerosis, and Volunteers With Idiopathic Pulmonary Fibrosis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Contineum Therapeutics · Industry
• Sex: All
• Age: 25 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF). The purpose of this study is to find out how much of the study drug gets into the brain and lung, and what the side effects and blood levels of the study drug are in healthy volunteers and patients. Participants will: * Take a single dose of the study drug * Give many samples of blood and urine * Have multiple PET scans

Conditions

• Idiopathic Pulmonary Fibrosis (IPF)
• Idiopathic Pulmonary Fibrosis
• Multiple Sclerosis
• Multiple Sclerosis, MS
• Multiple Sclerosis, Primary Progressive
• Multiple Sclerosis, Progressive
• Multiple Sclerosis, Secondary Progressive
• Healthy
• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	PIPE-791	Subjects will receive a single oral dose of PIPE-791.

Timeline

• Start date: 2024-12-09
• Primary completion: 2025-06-04
• Completion: 2025-06-12
• First posted: 2024-11-12
• Last updated: 2025-08-06

Locations

1 site across 1 country: United Kingdom